APA (7e ed.) Bronvermelding

Kubra Cerci & Pusem Patir. (2023). Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation. Global Journal of Medical and Clinical Case Reports - Peertechz Publications. https://doi.org/10.17352/2455-5282.000167

Chicago (17e ed.) Bronvermelding

Kubra Cerci en Pusem Patir. Ruxolitinib as a Therapy Choice for Refractory Pruritus in a Patient with Essential Thrombocythemia with CALR Mutation. Global Journal of Medical and Clinical Case Reports - Peertechz Publications, 2023. https://doi.org/10.17352/2455-5282.000167.

MLA (9e ed.) Bronvermelding

Kubra Cerci en Pusem Patir. Ruxolitinib as a Therapy Choice for Refractory Pruritus in a Patient with Essential Thrombocythemia with CALR Mutation. Global Journal of Medical and Clinical Case Reports - Peertechz Publications, 2023. https://doi.org/10.17352/2455-5282.000167.